Get it on Google Play

SELLAS Life Sciences hits 80th event in AML phase 3 trial

October 28, 2026 8:35 AM EDT Send to a Friend
SELLAS Life Sciences Group (NASDAQ: SLS) announced that its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS) in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login